Last reviewed · How we verify
Comparator: etoricoxib
Comparator: etoricoxib is a Selective COX-2 inhibitor (coxib) Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.
Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.
Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.
At a glance
| Generic name | Comparator: etoricoxib |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Etoricoxib is a selective COX-2 inhibitor that preferentially blocks the COX-2 enzyme over COX-1, thereby reducing the production of pro-inflammatory prostaglandins while sparing the protective effects of COX-1-derived prostaglandins in the gastrointestinal tract and kidneys. This selective mechanism provides anti-inflammatory and analgesic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Acute pain
- Chronic pain conditions
Common side effects
- Hypertension
- Edema
- Dyspepsia
- Headache
- Dizziness
Key clinical trials
- An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064) (PHASE3)
- A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED) (PHASE4)
- Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED) (PHASE3)
- A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED) (PHASE3)
- A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED) (PHASE4)
- A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED) (PHASE3)
- Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED) (PHASE3)
- An Investigational Drug in Patients With Osteoarthritis (0663-073) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: etoricoxib CI brief — competitive landscape report
- Comparator: etoricoxib updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Comparator: etoricoxib
What is Comparator: etoricoxib?
How does Comparator: etoricoxib work?
What is Comparator: etoricoxib used for?
Who makes Comparator: etoricoxib?
What drug class is Comparator: etoricoxib in?
What development phase is Comparator: etoricoxib in?
What are the side effects of Comparator: etoricoxib?
What does Comparator: etoricoxib target?
Related
- Drug class: All Selective COX-2 inhibitor (coxib) drugs
- Target: All drugs targeting COX-2 (Cyclooxygenase-2)
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Ankylosing spondylitis
- Compare: Comparator: etoricoxib vs similar drugs
- Pricing: Comparator: etoricoxib cost, discount & access